The Complete 2012-13 Induced Pluripotent Stem Cell Industry Report
Aarkstore Enterprise (India), 17th June , 2013 : Stem cell research and experimentation has been in process for well over five decades, as stem cells have the unique ability to divide and replicate repeatedly. In addition, their “unspecialized” nature allows them to differentiate into a wide variety of specialized cell types. The possibilities arising from these characteristics has caused great commercial interest, with potential applications ranging from the use of stem cells in reversal or treatment of disease, to targeted cell therapy, tissue regeneration, pharmacological testing on cell-specific tissues, and more. Diseases such as Huntington’s Chorea, Parkinson’s Disease, and spinal cord injuries are examples of clinical applications in which stem cells could offer benefits in halting or even reversing damage.
Traditionally, scientists have worked with both embryonic and adult stem cells as research tools. While the appeal of embryonic cells has been their ability to differentiate into any type of cell, there has been significant ethical, moral and spiritual controversy surrounding their use for research purposes. Although some adult stem cells do have differentiation capacity, it is often limited nature, which creates narrow options for use. Thus, induced pluripotent stem cells represent a promising combination of adult and embryonic stem cell characteristics.
Groundbreaking experimentation in 2006 led to the introduction of induced pluripotent stem cells (iPSC). These are adult cells which are isolated and then transformed into embryonic-like stem cells through the manipulation of gene expression, as well as other methods. Research and experimentation using mouse cells at Kyoto University in Japan was the first instance in which there was successful generation of the iPSC. In 2007, a series of follow-up experiments were done at Kyoto University in Japan in which human adult cells were transformed into iPSC cells.
While there has been continued excitement at the prospect of what such artificially re-manufactured cells could contribute to medical advances, there have also been issues along the way. By 2010, there were a number of private companies that were ready to capitalize on the breakthrough technology that iPSCs represent. One such company, Advanced Cell Technology in Worcester, Massachusetts, discovered several problematic issues while conducting experiments for the purpose of applying for U.S. Food and Drug Administration approval to use iPSC in therapeutic applications. Concerns such as premature cell death, mutation into cancer cells, and low proliferation rates were some of the problems that surfaced.
Continued research and experimentation has resulted in numerous advances over the last few years. In one example, the University of Michigan announced in “Circulation Research” (2012) that they had developed innovative methods for use of induced pluripotent stem cells derived from skin biopsies to create cardiac muscle cells. This accomplishment quickly fueled other research into the use of iPSCs for the reversal and repair of diseased heart tissue.
Similar advances will continue to be perfected for use of reprogrammed adult cells in the treatment of other diseases and disorders. Original techniques for iPSC production, such as viral induced transcription processes, are being replaced with newer technologies as private industries join with the scientific community to develop safe and efficient methods of iPSC production. With sustained research and experimentation, established guidelines for effective production of iPSC will be commonplace.
In summary, induced pluripotent stem cells represent a promising tool for use in the reversal and repair of many previously incurable diseases.
To read Full report please check the link: http://www.aarkstore.com/reports/The-Complete-2012-13-Induced-Pluripotent-Stem-Cell-Industry-Report-231968.html
Other Important Reports:
Mesenchymal Stem Cells – Advances & Applications
Capitalizing on Opportunities in Cord Blood Industry Growth (2013 Version)
For More details please contact:
Email: email@example.com | firstname.lastname@example.org
24/7 Online Support: (+91) 8149852585
ListFree.org: Embedded data.